Malignancy‐Associated Acquired Vulvar Lymphangioma Circumscriptum: A Clinicopathologic Study of 71 Cases

Background

Acquired lymphangioma circumscriptum of the vulva is rare and can occur subsequent to malignancies of the anogenital and pelvic region. We sought to investigate the clinicopathologic characteristics of malignancy-associated acquired vulvar lymphangioma circumscriptum (AVLC).

Methods

We identified all cases of AVLC within our institution with history of prior malignancy between 2005 - 2021. A similar search was performed in the PubMed database to identify published cases to date. The clinical and histopathologic information was recorded.

Results

A total of 71 cases were identified. The most common preceding malignancy was cervical carcinoma (71.8%, 51/71). 91.4% (64/70) of patients underwent radiation therapy and 70.2% (40/57) underwent lymph node dissection. Median interval between the diagnosis of malignancy and AVLC was 10 years (range 0-32 years). AVLC frequently presented as vesicular (31.6%, 18/57) or verrucous (28.1%, 16/57) lesions clinically. Common treatments for AVLC included excision (53.1%, 26/49) and laser therapy (16.3%, 8/49) with an overall recurrence rate of 42.9% (24/56) at a median follow-up interval of 1.8 years (range 0.04-32.3 years).

Conclusion

AVLC is a rare, late complication of anogenital and pelvic malignancies causing debilitating physical symptoms and psychological stress. Further studies are warranted to determine the most effective treatment modalities to mitigate recurrence.

This article is protected by copyright. All rights reserved.

留言 (0)

沒有登入
gif